Showing 401 - 420 results of 64,576 for search '(( 5 ((ppm decrease) OR (a decrease)) ) OR ( 5 ((non decrease) OR (nn decrease)) ))', query time: 1.22s Refine Results
  1. 401
  2. 402

    Related to Fig 5A. by Rani Moran (3315630)

    Published 2021
    “…<p>The findings for vegetables were similar to the findings for animal reported in the main text: we found a positive effect for the high-vegetable reward (b = 0.24, t(1736) = 4.33, p = 2e-5) and non-significant effects for the low (b = -0.11, t(1736) = -1.42, p = .156) and unrelated (b = 0.08, t(1736) = 1.88, p = .06) vegetable-reward. …”
  3. 403
  4. 404
  5. 405
  6. 406

    Subgroup analyses of the association between decreases in serum UA levels and poor functional outcome at 3 months. by Kuniyuki Nakamura (13040299)

    Published 2023
    “…<p>The ORs and 95% CIs of poor functional outcome (defined as an mRS score of 3–6 at 3 months) are shown according to UA decrease rate grade (G1 to G4) in each subgroup. The subgroups included (<b>A</b>) age (<75 or ≥75 years), (<b>B</b>) sex (women or men), (<b>C</b>) stroke subtype (non-cardioembolic or cardioembolic), (<b>D</b>) neurological severity (NIHSS <5 or ≥5), (<b>E</b>) CKD (presence or absence), and (<b>F</b>) UA level on admission (<292 or ≥292 μmol/L for women, <351 or ≥351 μmol/L for men). …”
  7. 407
  8. 408

    Supplementary Material for: Enhanced Recovery after Surgery for Radical Cystectomy Decreases Postoperative Complications at Different Times by Lannes F. (11465377)

    Published 2021
    “…Mean length of stay did not differ significantly between ERAS and non-ERAS groups (12.7 ± 6.2 and 13.1 ± 5.7 days, respectively; <i>p</i> = 0.743). …”
  9. 409
  10. 410
  11. 411

    Changes to chromatin state with PRMT5 inhibition. by Shelby L. Sloan (10803222)

    Published 2021
    “…At a FDR of 10%, more genomic sites show decreased accessibility than increased. …”
  12. 412

    Table2_Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients.docx by Peng Cao (107508)

    Published 2022
    “…Creatinine clearance (CrCl) was identified as a covariate to CL, and ERCC1 (rs3212986) and CYP3A5 (rs776746) gene polymorphisms as covariates to Q. …”
  13. 413

    Table1_Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients.xlsx by Peng Cao (107508)

    Published 2022
    “…Creatinine clearance (CrCl) was identified as a covariate to CL, and ERCC1 (rs3212986) and CYP3A5 (rs776746) gene polymorphisms as covariates to Q. …”
  14. 414

    Table1_Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients.xlsx by Peng Cao (107508)

    Published 2022
    “…Creatinine clearance (CrCl) was identified as a covariate to CL, and ERCC1 (rs3212986) and CYP3A5 (rs776746) gene polymorphisms as covariates to Q. …”
  15. 415

    Table2_Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients.docx by Peng Cao (107508)

    Published 2022
    “…Creatinine clearance (CrCl) was identified as a covariate to CL, and ERCC1 (rs3212986) and CYP3A5 (rs776746) gene polymorphisms as covariates to Q. …”
  16. 416
  17. 417
  18. 418
  19. 419
  20. 420